White Paper: Valuation of Your Early Drug Candidate

A "No-Formulas" Tour of Valuation

Biotech companies seek partnerships (collaborations, licensing deals, joint ventures, etc) to advance their drug candidates and raise funds. They frequently ask "How much is this drug candidate worth to a partner?" In this new white paper, author Linda Pullan reviews the different techniques, key variables, and characteristics of what makes a drug candidate more valuable to a partner. Find out how valuation gets translated to deal terms and get a clear, conceptual framework for your drug's valuation.


the white paper